AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04311229 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: contol group
Description: Wounds were finally covered with gauze dressing soaked with saline. Wounds were treated three times a day, and measurements were repeated every 48 hours. Every wound was measured a total of four times: one pre-treatment (baseline) and three post-treatment measurements.
Study NCT01714557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin
Description: 4.0g q8h 3-5 days
Study NCT01714557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam combination product
Description: 4.5g q8h 3-5 days
Study NCT00251407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
Study NCT00251407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT-11
Description: Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
Study NCT00947570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for anxiety
Description: 10 sessions delivered over the course of 14 weeks and aimed at reducing pathological behaviors and patterns of thought
Study NCT03531437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.5 mg estradiol and 2.5 mg nomegestrol acetate
Study NCT03531437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15 µg ethinylestradiol and 60 µg gestodene
Study NCT02491437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 30 mg
Description: Oral Dydrogesterone 10 mg tablets tid
Study NCT02491437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravaginal progesterone gel 90 mg
Study NCT00782015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Almonds
Description: 3 oz. of almonds per day, supplied as 1 oz. snack packs to be consumed for 6 weeks.
Study NCT00782015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator:
Description: NCEP Step 2 diet
Study NCT03152916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3d printing personalized plate
Description: 3d printing personalized plate will be used in the subtalar arthrodensis
Study NCT02258009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg intravitreal injections
Study NCT02258009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: 2 mg intravitreal injections
Study NCT03238586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WELL Program
Study NCT02419183 — intervention group
Intervention type: OTHER
Intervention: SAMSTAR
Description: This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
Study NCT02419183 — intervention group
Intervention type: OTHER
Intervention: RAVLT
Description: This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
Study NCT01407822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
Study NCT02669004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent bolus epidural morphine
Description: morphine given with patient- controlled intermittent bolus epidural, 50 µg/kg in 10 mL bolus, lockout time 1 hour, no infusion
Study NCT02669004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous epidural morphine
Description: morphine given with patient- controlled continuous epidural, initial setting loading morphine 0.02mg/kg in 8mL, was maintained 0.01 mg/kg continuous infusion 4mL, 0.05 mg/kg 2mL bolus dose. 30 minute lock-out interval. 4 hour limit was 4 mg/kg.
Study NCT00138034 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous coronary intervention (PCI)
Description: PCI with bare metal stent placement of the culprit lesion the in the infarct related artery
Study NCT00138034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: PCI with bare metal stent placement of the culprit lesion the in the infarct related artery
Study NCT01986569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]fluoroestradiol (FES)
Description: \[18F\]FES PET/CT will be performed 90 min (± 10 min) after administration of \[18F\]FES. Patients will undergo core needle biopsy or surgery within 15 days after \[18F\]FES PET; or patients will undergo core needle biopsy within 30 days before \[18F\]FES PET. Experienced pathologists will determine metastatic/recurrent disease, and tumor histology including IHC. Patient will undergo surgery, radiation therapy or systemic therapy according to the results of staging workup, histology and biomarkers.
Study NCT03705962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin
Study NCT03705962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: normal saline
Study NCT01996137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VASST II treadmill
Description: Supervised treadmill training under physiotherapist
Study NCT01407822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine/cisplatin
Description: In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
Study NCT01331122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: droxidopa
Description: Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes two crossover periods of up to a 2 week titration period followed by a 4 week treatment period,with a washout between crossover periods.
Study NCT04548687 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carbon dioxide insufflation
Description: Carbon dioxide insufflation at a rate of 5 l / min. through the Redon drainage during cardiac surgery (minimally invasive or repeated) during cardiopulmonary bypass
Study NCT04548687 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: No carbon dioxide insufflation
Description: standard methods of deaeration of cardiac cavities: manual method, change in body position, through the cannula of the ascending aorta, through the drainage of the left ventricle
Study NCT03422406 — intervention group
Intervention type: OTHER
Intervention: Dietary iodine intake restriction
Description: All subjects with excessive iodine load were recommended by nutritionists to restrict dietary iodine intake, and resume iodine-containing supplements and foods until their iodine status return to normal. However, in this observational study, the intervention was a regular management in prenatal care, and not assigned by investigator of the study.
Study NCT00908206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK598809
Description: Subjects will receive a single 175 mg oral dose of GSK598809.
Study NCT01331122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: droxidopa
Description: Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes two crossover periods of up to a 2 week titration period followed by a 4 week treatment period,with a washout between crossover periods.
Study NCT03354078 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interrupted sutures
Description: The way of closing subcutaneous tissue either by interrupted
Study NCT03354078 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continous sutures
Description: The way of closure of subcutanous tissue is by continous sutures
Study NCT03352414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan
Description: alvimopan pill
Study NCT03352414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill
Study NCT04758273 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: medium dosage inactivated SARS-CoV-2 vaccine
Description: medium dosage
Study NCT04758273 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dosage inactivated SARS-CoV-2 vaccine
Description: high dosage
Study NCT03890406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium: PTC(Post-tetanic count) 1~2
Description: Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.
Study NCT03890406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium: TOF(Train-of-four) 1~2
Description: Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
Study NCT01816529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem Hydrochloride 2% Cream
Description: 0.2 g applied topically to the infrascapular area of the back.
Study NCT04758273 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01816529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Vehicle Cream, 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
Study NCT02028429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil.
Description: Arm 1 :Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
Study NCT03943758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prepackaged Low-residue diet
Description: Subjects in the prepackaged Low-residue diet group were given 6 packs (60g/pack) pre-packaged formula LRD and asked to use the formula according to individual needs prior to colonoscopy.
Study NCT03943758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Self-prepared Low-residue diet
Description: Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy.
Study NCT01816529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% solution of sodium lauryl sulfate (SLS)
Description: 0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
Study NCT01816529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (0.9%)
Description: 0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
Study NCT02423993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education by structured programme
Description: Thе structured programme was developed in Endocrinology Research Centre. It is based on the following principles: education in group setting, using structured program; intensive insulin treatment using insulin pumps; self-adjustment of insulin dose and pump settings; intensive self-monitoring of blood glucose, including continuous glucose monitoring in real-time (CGM-RT); flexible physical activities and meals regimen (liberal diet, based on carbohydrates account using bread units; possible shifts of meals schedule and volume supported by appropriate treatment adjustment). Duration of education course - 8 days (35-37 hours); planned group volume is 7-10 patients.
Study NCT02423993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSII
Description: The intensified insulin therapy by means of continuous subcutaneous insulin infusion will be provide by Medtronic insulin pumps: Paradigm MMT-712/715, Paradigm Real-Time MMT-722, Paradigm VEO MMT-754.
Study NCT02423993 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CSII
Description: The intensified insulin therapy by means of continuous subcutaneous insulin infusion will be provide by Medtronic insulin pumps: Paradigm MMT-712/715, Paradigm Real-Time MMT-722, Paradigm VEO MMT-754.
Study NCT02423993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM-RT
Description: Continuous glucose monitoring (CGM) will be provide by means of Paradigm Real-Time MMT-722 and Paradigm VEO MMT-754 Medtronic sensor-augmented insulin pumps. For monitoring the Sof-Sensor and MiniLink transmitter (Medtronic) will be use. Each sensor will be use for 6 days. CGM will be use for self-monitoring of blood glucose on permanent basis (more than 6 days per week) within 4 month.
Study NCT02423993 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CGM-RT
Description: Continuous glucose monitoring (CGM) will be provide by means of Paradigm Real-Time MMT-722 and Paradigm VEO MMT-754 Medtronic sensor-augmented insulin pumps. For monitoring the Sof-Sensor and MiniLink transmitter (Medtronic) will be use. Each sensor will be use for 6 days. CGM will be use for self-monitoring of blood glucose on permanent basis (more than 6 days per week) within 4 month.
Study NCT02423993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Screening for Complications
Description: To assess diabetic retinopathy a fundoscopy will be held. Diabetic nephropathy will be assessed by microalbuminuria screening, serum creatinine evaluation and calculation of CKD-EPI glomerular filtration rate. Diabetic neuropathy will be assessed by all kinds of sensitivity evaluation (vibrating, tactile, temperature).
Study NCT02253706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen supplementation
Description: High-flow nasal ventilation: This will be carried out using the Precision Flow device (Opti-Flow, Auckland, New Zealand). This device is intended to add warm moisture to breathing gases from an external source. Flow rate via the nasal cannula will be kept at 50 Liters/min and fractional inspired oxygen concentration will be set at 0.35.
Study NCT02253706 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low flow nasal oxygen supplementation
Description: Low-flow nasal ventilation: This will be carried out using a regular nasal cannula fed with oxygen at flow rates from 2 to 6 liters/minute.
Study NCT03367130 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mobile phone reminder
Description: Intervention described already in arm/group descriptions.
Study NCT03367130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone reminder
Description: Intervention described already in arm/group descriptions.
Study NCT01165723 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
Study NCT06490159 — intervention group
Intervention type: DRUG
Intervention: Paclitaxel
Description: Gastric cancer second-line chemotherapy
Study NCT00781261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Subjects in the intervention group B will be given 5mg Zoledronic acid as a single injection.
Study NCT00781261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the control group will receive a placebo drug for a similar period
Study NCT03787615 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: sipIT tools
Description: Just in time drinking detection tools to promote increase fluid consumption
Study NCT00493779 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Blood Collection
Description: 4 weeks
Study NCT00895037 — intervention group
Intervention type: DRUG
Intervention: ReFacto AF (Moroctocog alfa)
Description: Patients will be treated with intravenous infusion of ReFacto AF per dosing and frequency as prescribed by the subjects' treating physician. ReFacto AF® will be prescribed in the context of routine clinical practice in Germany and Austria, respectively
Study NCT01383850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NCPAP + standard air
Description: NCAP (SiPAP, Vyasis) was used to administer standard air
Study NCT01383850 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP + standard air
Description: NCAP (SiPAP, Vyasis) was used to administer standard air
Study NCT01383850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NCPAP + Heliox
Description: Heliox21 (mixture of Helium 80%- Oxygen 20%) (BOC Medical UK- The Linde group) was stored in 10 liter cylinders and administrated through NCPAP for 12 hours (study period) starting from randomization.
Study NCT01383850 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP + Heliox
Description: Heliox21 (mixture of Helium 80%- Oxygen 20%) (BOC Medical UK- The Linde group) was stored in 10 liter cylinders and administrated through NCPAP for 12 hours (study period) starting from randomization.
Study NCT02630290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine
Study NCT02630290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Dexmedetomidine
Description: Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine plus low-dose (30 microg) dexmedetomidine
Study NCT00351351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyberwand
Description: FDA approved - dual probe intracorporeal lithotrite
Study NCT00351351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single probe ultrasonic
Description: FDA-approved - single probe ultrasonic
Study NCT04063319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Description: The set up in the high-fidelity simulation intervention is a deteriorating patient scenario.
Study NCT01010815 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy biopsy
Description: Colonoscopy biopsy will be performed in rectum, ascending and descending colon at study entry
Study NCT01010815 — intervention group
Intervention type: OTHER
Intervention: stool collection
Description: Stool will be collected from participants at study entry
Study NCT01010815 — intervention group
Intervention type: PROCEDURE
Intervention: colonoscopy biopsy
Description: colonoscopy biopsy will be conducted in rectum, ascending and descending colon from participants 2 times during study - at active phase and inactive phase
Study NCT01010815 — intervention group
Intervention type: OTHER
Intervention: stool collection
Description: stool will be collected from participants 2 times during study - at active phase and inactive phase
Study NCT02116894 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-03446962
Description: PF-03446962 will be an investigational formulation supplied by Pfizer . PF-03446962 injection, 10 mg/mL is presented as a sterile solution for IV administration in a formulation consisting of precedented excipients. We will be administering PF-03446962 intravenously at a starting dose of 4.5 mg/kg and escalating to up to 7 mg/kg.
Study NCT02116894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: We will be administering regorafenib on-label for the indication of metastatic colorectal cancer. The indicated dose is 160 mg once daily for the first 21 days of a 28 day cycle. We will start at a regorafenib dose of 120 mg in the combination therapy, but may increase to 160 mg during dose escalation.
Study NCT00668447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Isolate
Description: 20 grams of powder mixed in beverages or food daily for one year
Study NCT00668447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy Isolate
Description: 20 grams of powder mixed in beverages or food daily for one year
Study NCT00668447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control protein
Description: 20 grams of powder mixed in beverages or food daily for one year
Study NCT00668447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control protein
Description: 20 grams of powder mixed in beverages or food daily for one year
Study NCT00668447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Novasoy isoflavones
Description: 3 tablets daily for one year
Study NCT00668447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Novasoy isoflavones
Description: 3 tablets daily for one year
Study NCT00668447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablets
Description: 3 tablets daily for one year
Study NCT00668447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: 3 tablets daily for one year
Study NCT03608306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer
Description: enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
Study NCT03608306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bulk-fill glass hybrid restorative
Description: It's a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.